The UCSF Children’s Cancer Program offers a wide range of clinical trials for children and young adults with cancer in the San Francisco Bay Area, Northern California, and western United States. We are a designated Children's Oncology Group (COG) Phase 1 center. We also have studies from New Approaches to Neuroblastoma Therapy (NANT), Pacific Pediatric Neuro-Oncology Consortium (PNOC), Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), Sarcoma Alliance for Research Through Collaboration (SARC), pharmaceutical industry, and university institutions. Many of our trials are available for patients up to 30 years of age.

For patients with newly diagnosed cancer, most clinical trials are offered through our participation in the national Children’s Oncology Group. A list of current open trials appropriate for newly diagnosed patients can be found here.

For patients with relapsed or refractory cancer, we strive to provide patients access to the newest treatment options in the form of phase 1 and phase 2 clinical trials. Our current open phase 1 and 2 clinical trials are listed below, according to disease category.

If you are interested in learning more about any of these trials, please contact us at 415-476-3831 or cancerclinicaltrials@peds.ucsf.edu.

 

ADVL1217: A Phase 1 Study of MK-1775 Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas

Investigator: Sabine Mueller
Status: Open

Novartis CLEE011X2102: A phase I, multi-center, open-label study of LEE011 in patients with malignant rhabdoid tumors and neuroblastoma

Investigator: Steven DuBois
Status: Open

PNOC001: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children

Investigator: Daphne Haas-Kogan
Status: Open

PNOC002: Safety and Phase 0 Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children withRecurrent/Refractory BRAFV600E-mutant astrocytomas

Investigator: Theodore Nicolaides
Status: Open

DFCI # 10-321: Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Investigator: Anuradha Banerjee
Status: Open

PBTC-029: A Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Investigator: Anuradha Banerjee
Status: Phase 1 closed, waiting for Phase 2 to open

Siro topo cyclo: A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and Refractory Solid Tumors

Investigator: Steven DuBois
Status: Open

ADVL1211: A Phase 1 study of XL184 (Cabozantinib) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors

Investigator: Steven DuBois
Status: Open

ACNS0821: Temozolomide with Irinotecan Versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Investigator: Anuradha Banerjee
Status: Open

ACNS0927: A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)

Investigator: Anuradha Banerjee
Status: Open, in Phase 2

ACNS1022: A Phase II Randomized Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas

Investigator: Anuradha Banerjee
Status: Open

ADVL1011: A Phase 1 Study of JAK Inhibition in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

Investigator: Mignon Loh
Status: Open

ADVL1114: A Phase 1 Study of Temsirolimus in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma

Investigator: Steven DuBois
Status: Open

AALL1121: A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)


Investigator: Steven DuBois
Status: Closed for Phase 1, Waiting on Phase 2 Opening

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL)

Investigator: Steven DuBois
Status: Open

TACL 2008-002: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse)

Investigator: Steven DuBois
Status: Open

TACL 2009-003: A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL

Investigator: Steven DuBois
Status: Open

TACL 2009-008:  A Phase I Study of GNKG168 in Pediatric Patients with Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Investigator: Steven DuBois
Status: Open

TACL 2009-012: A Phase I Dose Finding Study of Panobinostat In Children with Refractory Hematologic Malignancies 
*histone deacetylase (HDAC) inhibitor

Investigator: Steven DuBois
Status: Open

TACL 2011-002: A Phase I Study of 5-Azacytidine in Combination with Chemotherapy for Children with Relapsed or Refractory ALL or AML

Investigator: Steven DuBois
Status: Open

DFCI #11-237: A feasibility trial of everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction chemotherapy in pediatric patients with relapsed acute lymphoblastic leukemia (ALL)

Investigator: Mignon Loh
Status: Open

Novartis CLEE011X2102: A phase I, multi-center, open-label study of LEE011 in patients with malignant rhabdoid tumors and neuroblastoma

Investigator: Steven DuBois
Status: Open

Siro topo cyclo: A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and Refractory Solid Tumors

Investigator: Steven DuBois
Status: Open

NANT 2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma

Investigator:  Katherine Matthay
Status:  Open

NANT 2007-02: A Phase I Study Of Bevacizumab With Bolus And Metronomic Cyclophosphamide And Zoledronic Acid In Children With Recurrent Or Refractory Neuroblastoma

Investigator:  Katherine Matthay
Status:  Open

NANT 2008-02: Phase I Study of Vorinostat in Combination with 13-Cis-Retinoic Acid in Patients with Refractory/Recurrent Neuroblastoma

Investigator:  Katherine Matthay
Status:  Open

NANT 2009-03: Phase I/II Study of MLN8237 in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Investigator: Steven DuBois
Status: Open

NANT 2011-04: Lenalidomide and Monoclonal Antibody With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Investigator: Katherine Matthay
Status: Open

ADVL0912: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Investigator: Steven DuBois
Status:  Open

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL)

Investigator: Steven DuBois
Status: Open

ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Chimeric 14.18 Antibody (ch14.18) in Children with Refractory, Relapsed or Progressive Neuroblastoma

Investigator: Katherine Matthay
Status: Open

Siro topo cyclo: A Phase I Study of Sirolimus in Combination with Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults with Relapsed and Refractory Solid Tumors

Investigator: Steven DuBois
Status: Open

IA melphalan and chemo: A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy In Children with Newly Diagnosed Advanced Inra-Ocular Retinoblastoma

Investigator: Katherine Matthay
Status: Open

Amgen 20050252: A Phase I Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors

Investigator: Anuradha Banerjee
Status: Open

ADVL1211: A Phase 1 study of XL184 (Cabozantinib) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors

Investigator: Steven DuBois
Status: Open

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL)
Investigator: Steven DuBois
Status: Open

ADVL1213: A Phase 1 Study of the TEM-1 Antibody, MORAb-004 , in Children with Recurrent or Refractory Solid Tumors
Investigator: Steven DuBois
Status: Open